Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.4620-4622 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4622 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 4620 |
| container_title | Blood |
| container_volume | 140 |
| creator | Mailankody, Sham Matous, Jeffrey V. Liedtke, Michaela Sidana, Surbhi Oluwole, Olalekan O. Mohan, Meera Cruz, Jose C. Nath, Rajneesh Anwer, Faiz Rossi, Adriana Htut, Myo Malik, Shahbaz A. Ghatta, Srinivas Dillon, Myles Ying, Wendy Navale, Lynn Karski, Erin E. Balakumaran, Arun Kumar, Shaji K. |
| description | |
| doi_str_mv | 10.1182/blood-2022-158231 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_158231</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122035704</els_id><sourcerecordid>S0006497122035704</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1851-8a2bb3c15744457873eb76b1eb8b5dbbfad99f4598c4b10803e7caae2a5fb1583</originalsourceid><addsrcrecordid>eNp9kMtOwzAURC0EEuXxAez8AwZfJ24csQrlKaUCVe06sp2b1sjUkR2QuuPTSSlrFqNZndHoEHIF_BpAiRvjQ2iZ4EIwkEpkcEQmIIVinAt-TCac8ynLywJOyVlK75xDngk5Id-rrfvCmLSnq77VA7b0baMTUqD3etD02a03fsyQ6CJ4pKGjlfdhjVt0llbbwbG72byiVV2_sgIkXW4w6n5HuxDpAr3uE7Y3C-yitkOIOzr_9IPrx6X5Dn340BfkpNM-4eVfn5PV48Ny9szq16eXWVUzC0oCU1oYk1mQRZ7nslBFhqaYGkCjjGyN6XRbll0uS2VzA1zxDAurNQotOzMayc4JHHZtDClF7Jo-ug8ddw3wZq-w-VXY7BU2B4Ujc3tgcDz25TA2yTrcWmxdRDs0bXD_0D_Et3mH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Mailankody, Sham ; Matous, Jeffrey V. ; Liedtke, Michaela ; Sidana, Surbhi ; Oluwole, Olalekan O. ; Mohan, Meera ; Cruz, Jose C. ; Nath, Rajneesh ; Anwer, Faiz ; Rossi, Adriana ; Htut, Myo ; Malik, Shahbaz A. ; Ghatta, Srinivas ; Dillon, Myles ; Ying, Wendy ; Navale, Lynn ; Karski, Erin E. ; Balakumaran, Arun ; Kumar, Shaji K.</creator><creatorcontrib>Mailankody, Sham ; Matous, Jeffrey V. ; Liedtke, Michaela ; Sidana, Surbhi ; Oluwole, Olalekan O. ; Mohan, Meera ; Cruz, Jose C. ; Nath, Rajneesh ; Anwer, Faiz ; Rossi, Adriana ; Htut, Myo ; Malik, Shahbaz A. ; Ghatta, Srinivas ; Dillon, Myles ; Ying, Wendy ; Navale, Lynn ; Karski, Erin E. ; Balakumaran, Arun ; Kumar, Shaji K.</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-158231</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.4620-4622</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1851-8a2bb3c15744457873eb76b1eb8b5dbbfad99f4598c4b10803e7caae2a5fb1583</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Mailankody, Sham</creatorcontrib><creatorcontrib>Matous, Jeffrey V.</creatorcontrib><creatorcontrib>Liedtke, Michaela</creatorcontrib><creatorcontrib>Sidana, Surbhi</creatorcontrib><creatorcontrib>Oluwole, Olalekan O.</creatorcontrib><creatorcontrib>Mohan, Meera</creatorcontrib><creatorcontrib>Cruz, Jose C.</creatorcontrib><creatorcontrib>Nath, Rajneesh</creatorcontrib><creatorcontrib>Anwer, Faiz</creatorcontrib><creatorcontrib>Rossi, Adriana</creatorcontrib><creatorcontrib>Htut, Myo</creatorcontrib><creatorcontrib>Malik, Shahbaz A.</creatorcontrib><creatorcontrib>Ghatta, Srinivas</creatorcontrib><creatorcontrib>Dillon, Myles</creatorcontrib><creatorcontrib>Ying, Wendy</creatorcontrib><creatorcontrib>Navale, Lynn</creatorcontrib><creatorcontrib>Karski, Erin E.</creatorcontrib><creatorcontrib>Balakumaran, Arun</creatorcontrib><creatorcontrib>Kumar, Shaji K.</creatorcontrib><title>Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAURC0EEuXxAez8AwZfJ24csQrlKaUCVe06sp2b1sjUkR2QuuPTSSlrFqNZndHoEHIF_BpAiRvjQ2iZ4EIwkEpkcEQmIIVinAt-TCac8ynLywJOyVlK75xDngk5Id-rrfvCmLSnq77VA7b0baMTUqD3etD02a03fsyQ6CJ4pKGjlfdhjVt0llbbwbG72byiVV2_sgIkXW4w6n5HuxDpAr3uE7Y3C-yitkOIOzr_9IPrx6X5Dn340BfkpNM-4eVfn5PV48Ny9szq16eXWVUzC0oCU1oYk1mQRZ7nslBFhqaYGkCjjGyN6XRbll0uS2VzA1zxDAurNQotOzMayc4JHHZtDClF7Jo-ug8ddw3wZq-w-VXY7BU2B4Ujc3tgcDz25TA2yTrcWmxdRDs0bXD_0D_Et3mH</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Mailankody, Sham</creator><creator>Matous, Jeffrey V.</creator><creator>Liedtke, Michaela</creator><creator>Sidana, Surbhi</creator><creator>Oluwole, Olalekan O.</creator><creator>Mohan, Meera</creator><creator>Cruz, Jose C.</creator><creator>Nath, Rajneesh</creator><creator>Anwer, Faiz</creator><creator>Rossi, Adriana</creator><creator>Htut, Myo</creator><creator>Malik, Shahbaz A.</creator><creator>Ghatta, Srinivas</creator><creator>Dillon, Myles</creator><creator>Ying, Wendy</creator><creator>Navale, Lynn</creator><creator>Karski, Erin E.</creator><creator>Balakumaran, Arun</creator><creator>Kumar, Shaji K.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma</title><author>Mailankody, Sham ; Matous, Jeffrey V. ; Liedtke, Michaela ; Sidana, Surbhi ; Oluwole, Olalekan O. ; Mohan, Meera ; Cruz, Jose C. ; Nath, Rajneesh ; Anwer, Faiz ; Rossi, Adriana ; Htut, Myo ; Malik, Shahbaz A. ; Ghatta, Srinivas ; Dillon, Myles ; Ying, Wendy ; Navale, Lynn ; Karski, Erin E. ; Balakumaran, Arun ; Kumar, Shaji K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1851-8a2bb3c15744457873eb76b1eb8b5dbbfad99f4598c4b10803e7caae2a5fb1583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mailankody, Sham</creatorcontrib><creatorcontrib>Matous, Jeffrey V.</creatorcontrib><creatorcontrib>Liedtke, Michaela</creatorcontrib><creatorcontrib>Sidana, Surbhi</creatorcontrib><creatorcontrib>Oluwole, Olalekan O.</creatorcontrib><creatorcontrib>Mohan, Meera</creatorcontrib><creatorcontrib>Cruz, Jose C.</creatorcontrib><creatorcontrib>Nath, Rajneesh</creatorcontrib><creatorcontrib>Anwer, Faiz</creatorcontrib><creatorcontrib>Rossi, Adriana</creatorcontrib><creatorcontrib>Htut, Myo</creatorcontrib><creatorcontrib>Malik, Shahbaz A.</creatorcontrib><creatorcontrib>Ghatta, Srinivas</creatorcontrib><creatorcontrib>Dillon, Myles</creatorcontrib><creatorcontrib>Ying, Wendy</creatorcontrib><creatorcontrib>Navale, Lynn</creatorcontrib><creatorcontrib>Karski, Erin E.</creatorcontrib><creatorcontrib>Balakumaran, Arun</creatorcontrib><creatorcontrib>Kumar, Shaji K.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mailankody, Sham</au><au>Matous, Jeffrey V.</au><au>Liedtke, Michaela</au><au>Sidana, Surbhi</au><au>Oluwole, Olalekan O.</au><au>Mohan, Meera</au><au>Cruz, Jose C.</au><au>Nath, Rajneesh</au><au>Anwer, Faiz</au><au>Rossi, Adriana</au><au>Htut, Myo</au><au>Malik, Shahbaz A.</au><au>Ghatta, Srinivas</au><au>Dillon, Myles</au><au>Ying, Wendy</au><au>Navale, Lynn</au><au>Karski, Erin E.</au><au>Balakumaran, Arun</au><au>Kumar, Shaji K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>4620</spage><epage>4622</epage><pages>4620-4622</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-158231</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.4620-4622 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_158231 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T13%3A39%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Universal%20Updated%20Phase%201%20Data%20Highlights%20Role%20of%20Allogeneic%20Anti-BCMA%20ALLO-715%20Therapy%20for%20Relapsed/Refractory%20Multiple%20Myeloma&rft.jtitle=Blood&rft.au=Mailankody,%20Sham&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=4620&rft.epage=4622&rft.pages=4620-4622&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-158231&rft_dat=%3Celsevier_cross%3ES0006497122035704%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122035704&rfr_iscdi=true |